文献速递妇科

电针治疗绝经过渡期症状:一项随机对照试验

Acupuncture for symptoms in menopause transition: a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2018-08-17

一项在中国大陆开展的前瞻性多中心随机参与者盲法试验,将360名绝经过渡期女性随机分为电针组与假电针组,各180例,接受8周共24次治疗并随访24周。第8周时,电针组绝经评定量表总分较基线下降6.3,假电针组下降4.5,组间差异1.8(95%CI 0.9-2.8;P=0.0002),小于5分的最小临床重要差异;作者结论认为8周电针治疗似乎未能缓解绝经症状,但似乎改善了生活质量。

要点

  • 第8周绝经评定量表总分下降:电针组6.3 vs 假电针组4.5,组间差异1.8(95%CI 0.9-2.8;P=0.0002)。
  • 组间差异小于5分的最小临床重要差异,作者认为电针似乎未能缓解绝经症状。
  • 绝经特异性生活质量问卷总分下降组间差异第8周5.7、第20周7.1、第32周8.4,大于4分的最小临床重要差异。

核心结论

  • 在绝经过渡期女性中,8周电针治疗似乎未能缓解绝经症状,尽管似乎改善了生活质量。
  • 试验结果的普适性可能受纳入参与者基线绝经症状较轻的限制。

研究设计与样本

  • 在中国大陆开展的前瞻性、多中心、随机、参与者盲法试验。
  • 受试者随机接受8周共24次传统穴位电针或非穴位假电针治疗,并随访24周。
  • 共纳入360名绝经过渡期伴有绝经相关症状的女性,电针组180例、假电针组180例,纳入时间为2013年6月9日至2015年12月28日。
  • 主要结局为第8周绝经评定量表总分较基线的变化;所有分析按意向性治疗原则进行,采用双侧P<0.05为显著。

主要发现

  • 第8周绝经评定量表总分较基线下降:电针组6.3(95%CI 5.0-7.7) vs 假电针组4.5(95%CI 3.2-5.8),组间差异1.8(95%CI 0.9-2.8;P=0.0002),小于5分的最小临床重要差异。
  • 平均24小时潮热评分下降的组间差异在第8周、第20周和第32周均显著,但均小于既往报告的最小临床重要差异。
  • 绝经特异性生活质量问卷总分下降的组间差异第8周为5.7、第20周为7.1、第32周为8.4,大于4分的最小临床重要差异。
  • 第8周和第20周卵泡刺激素、黄体生成素和雌二醇水平较基线的变化组间无差异(所有P>0.05),但卵泡刺激素/黄体生成素比值除外(第8周P=0.0024,第20周P=0.0499)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验结果的普适性可能受纳入参与者基线绝经症状较轻的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acupuncture has been used for women during menopause transition, but evidence is limited. OBJECTIVE: We sought to evaluate the efficacy of electroacupuncture on relieving symptoms of women during menopause transition. STUDY DESIGN: We conducted a prospective, multicenter, randomized, participant-blinded trial in China mainland. Subjects were randomized to receive 24 treatment sessions of electroacupuncture at traditional acupoints or sham electroacupuncture at nonacupoints over 8 weeks with 24 weeks' follow-up. Primary outcome was the change from baseline in the total score of Menopause Rating Scale at week 8. Secondary outcomes included the changes from baseline in the average 24-hour hot flash score, the Menopause Rating Scale subscale scores, the total score of Menopause-Specific Quality of Life Questionnaire and its subscales, and serum female hormones. All analyses were performed with a 2-sided P value of < .05 considered significant based on the intention-to-treat principle. RESULTS: A total of 360 women (180 in each group) with menopause-related symptoms during menopause transition were enrolled from June 9, 2013, through Dec 28, 2015. At week 8, the reduction from baseline in the Menopause Rating Scale total score was 6.3 (95% confidence interval, 5.0-7.7) in the electroacupuncture group and 4.5 (95% confidence interval, 3.2-5.8) in the sham electroacupuncture group with a between-group difference of 1.8 (95% confidence interval, 0.9-2.8; P = .0002), less than the minimal clinically important difference of 5 points' reduction. For secondary outcomes, the between-group differences for the decrease in the mean 24-hour hot flash score were significant at weeks 8, 20, and 32, but all were less than the minimal clinically important difference in previous reports. Interestingly, the between-group differences for the Menopause-Specific Quality of Life Questionnaire total score reduction were 5.7 at week 8, 7.1 at week 20, and 8.4 at week 32, greater than the minimal clinically important difference of 4 points. Changes from baseline in follicle-stimulating hormone, luteinizing hormone, and estradiol levels at weeks 8 and 20 (P > .05 for all), with the exception of follicle-stimulating hormone/luteinizing hormone ratios (P = .0024 at week 8 and .0499 at week 20), did not differ between groups. CONCLUSION: Among women during menopause transition, 8 weeks' electroacupuncture treatment did not seem to relieve menopausal symptoms, even though it appeared to improve their quality of life. Generalizability of the trial results may be limited by mild baseline menopausal symptoms in the included participants.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Ai Y, Wang W, et al. Acupuncture for symptoms in menopause transition: a randomized controlled trial. Am J Obstet Gynecol. 2018. PMID: 30125529. doi:10.1016/j.ajog.2018.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。